Home
Live Updates
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 : comparemela.com
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney...
Related Keywords
Japan ,
United States ,
American ,
Michellen Rheault ,
Brad Rovin ,
Nivi Nehra ,
Naomi Eichenbaum ,
Jula Inrig ,
Ohio State University Center ,
Division For Nephrology ,
Travere Therapeutics Inc ,
American Society Of Nephrology ,
Nasdaq ,
Division Of Pediatric Nephrology ,
Exchange Commission ,
Corporate Communications ,
Clinical Research Management ,
University Of Minnesota Medical School ,
American Society ,
Kidney Week ,
New England Journal ,
Medical Director ,
Pediatric Nephrology ,
Minnesota Medical School ,
Travere Therapeutics ,
Important Safety ,
Endothelin Receptor Antagonists ,
Upper Limit ,
Fetal Toxicity ,
Kidney Injury ,
Angiotensin System ,
Acid Reducing Agents ,
Steroidal Anti Inflammatory Agents ,
Including Selective ,
Increasing Serum Potassium ,
Reproductive Potential ,
Full Prescribing Information ,
Private Securities Litigation Reform Act ,
Markets ,
comparemela.com © 2020. All Rights Reserved.